-
Loading metrics
Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
- Shun Lu,
- Yongfeng Yu,
- Shijun Fu,
- Hongye Ren
x
- Published: October 23, 2018
- https://doi.org/10.1371/journal.pone.0205827
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
Loading metrics